New Targets for the Treatment of Hypertension and Associated Diseases

1. The CYP/20-HETE/GPR75 axis in hypertensionGhezal Froogh, Victor Garcia and Michal L. Schwartzman2. Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injuryJohn D Imig3. Pharmacological developments in antihypertensive treatment through nitric oxide-cGMP modulationAnnika A. Jüttner, A.H. Jan Danser and Anton J.M. Roks4. Sphingosine-1-phosphate and sphingosine-1-phosphate receptors in the cardiovascular system: Pharmacology and clinical implicationsSimona Federica Spampinato, Maria Angela Sortino and Salvatore Salomone5. Polymorphisms in common antihypertensive targets: Pharmacogenomic implications for the treatment of cardiovascular diseaseDominique Brown, Heather Alcala, Peter Oelschlaeger and Bradley T. Andresen6. Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertensionPrasad Chunduri, Shrey A. Patel and Scott P. Levick7. Cardiovascular effects of GLP-1 receptor agonismRaymond J. Winquist and Valentin K. Gribkoff8. ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and diseaseHaiFeng Yang and Raouf A. Khalil9. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncologyGiorgio Minotti, Pierantonio Menna, Massimiliano Camilli, Emanuela Salvatorelli and Roberto Levi